近距离放疗单药治疗适合 favorable 和部分 unfavorable 中危前列腺癌
该单中心回顾性分析纳入1622例中危前列腺癌患者,中位随访10.4年,评估近距离放疗单药治疗后的生化失败(BF)。单药治疗下,PSA≥10 ng/mL和cT2b-c疾病与BF相关;无这些风险因素者10年BF为5.8%,有者为17.2%。cT1-T2a/PSA<10组加ADT或EBRT均与BF无关;cT2b-T2c和/或PSA≥10亚组中ADT与BF相关而EBRT无关。
要点
- 近距离放疗单药适用于所有favorable中危和cT1-T2a/PSA<10的unfavorable中危患者。
- PSA≥10 ng/mL和cT2b-c疾病是单药治疗生化失败的独立风险因素。
- cT2b-T2c和/或PSA≥10亚组中,加用ADT与生化失败降低相关,加用EBRT无显著关联。
核心结论
- 近距离放疗单药治疗适合所有favorable中危和满足cT1-T2a/PSA<10标准的unfavorable中危前列腺癌。
研究设计与样本
- 单中心回顾性分析纳入1622例中危前列腺癌患者,接受近距离放疗(单药或联合ADT和/或EBRT),中位随访10.4年。
主要发现
- 单药治疗中,PSA≥10 ng/mL(调整sHR 3.01;95%CI 1.10-8.27;p=0.032)和cT2b-c疾病(调整sHR 4.52;95%CI 1.85-11.07;p=0.001)与生化失败相关。
- 无上述风险因素者单药治疗后10年生化失败率为5.8%(FIR 3.8%,UIR 8.8%),有风险因素者为17.2%(FIR 9.3%,UIR 23.9%)。
- cT1-T2a/PSA<10组中,加用ADT(sHR 0.90;95%CI 0.38-2.1;p=0.82)或EBRT(sHR 0.65;95%CI 0.36-1.18;p=0.16)与生化失败无关。
- cT2b-T2c和/或PSA≥10亚组中,ADT(sHR 0.33;95%CI 0.14-0.74;p=0.007)与生化失败相关,EBRT(sHR 0.66;95%CI 0.34-1.31;p=0.24)无关。
关键数值与推荐
- 生化失败定义为前列腺特异性抗原(PSA)>0.4 ng/mL。
临床怎么用
- 对favorable中危及cT1-T2a/PSA<10的unfavorable中危患者可考虑近距离放疗单药治疗。
- 对cT2b-T2c和/或PSA≥10的unfavorable中危患者,单药治疗生化失败风险较高,可考虑联合ADT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current National Comprehensive Cancer Network guidelines define brachytherapy monotherapy as a suitable treatment for favorable intermediate risk (FIR) and unfavorable intermediate risk (UIR) prostate cancer. Our objective is to define the subgroup of patients suitable for brachytherapy monotherapy. METHODS: We conducted a single-institutional retrospective analysis of intermediate risk prostate cancer, treated with brachytherapy with or without androgen deprivation therapy (ADT) and/or external beam radiation therapy (EBRT). The primary endpoint was biochemical failure (BF), defined as prostate specific antigen (PSA) > 0.4 ng/mL. For monotherapy, multivariate Fine-Gray analysis was used to identify risk factors associated with BF. Univariate analysis was performed to evaluate whether ADT and/or EBRT were associated with BF for patients without and with such factors. RESULTS: Among 1622 patients, the median follow-up was 10.4 years. For monotherapy, PSA ≥ 10 ng/mL (adjusted sHR 3.01; 95% CI: 1.10-8.27; p = 0.032) and cT2b-c disease (adjusted sHR 4.52; 95% CI: 1.85-11.07; p = 0.001) were associated with BF. The 10-year incidences of BF after monotherapy for patients without and with these risk factors were 5.8% (3.8% FIR, 8.8% UIR) versus 17.2% (9.3% FIR, 23.9% UIR), respectively. For the cT1-T2a/PSA < 10 risk group, neither the addition of ADT (sHR 0.90; 95% CI: 0.38-2.1; p = 0.82) nor EBRT (sHR 0.65; 95% CI: 0.36-1.18; p = 0.16) was associated with biochemical failure. For the cT2b-T2c and/or PSA ≥ 10 subgroup, ADT (sHR: 0.33; 95% CI: 0.14-0.74; p = 0.007) but not EBRT (sHR 0.66; 95% CI: 0.34-1.31; p = 0.24) was associated with BF. CONCLUSIONS: Brachytherapy monotherapy is suitable for all FIR, and UIR disease meeting cT1-T2a/PSA < 10 criteria.
引用
- King M, Mirić G, Galbreath R, et al. Brachytherapy monotherapy for favorable and select unfavorable intermediate risk prostate cancer. Prostate Cancer Prostatic Dis. 2025. PMID: 40935889. doi:10.1038/s41391-025-01021-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。